AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Veru Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SCF2T8
2.24▼ 0.05 (-2.18%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.29
Day's Range
2.22 – 2.32
52-Week Range
2.05 – 7.33
Volume
122.6K
Avg Volume
186.6K
Share Statistics
Shares Outstanding
Employees
20
Exchange
XNAS
Listed
1990-06-01
Share count as of August 6, 2026

Veru Inc. (VERU) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Veru Inc. (VERU)
What is Veru Inc.'s Market Cap?
Veru Inc.'s Market Cap is $38.2M, based on as-reported figures from SEC (XBRL) filings.
What is Veru Inc.'s Enterprise Value?
Veru Inc.'s Enterprise Value is $14.3M, based on as-reported figures from SEC (XBRL) filings.
What is Veru Inc.'s EV / EBITDA?
Veru Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Veru Inc.'s Net Income (TTM)?
Veru Inc.'s Net Income (TTM) is -$13.6M, based on as-reported figures from SEC (XBRL) filings.
What is Veru Inc.'s EBITDA?
Veru Inc.'s EBITDA is -$19.1M, based on as-reported figures from SEC (XBRL) filings.
What is Veru Inc.'s Diluted EPS (TTM)?
Veru Inc.'s Diluted EPS (TTM) is -0.80, based on as-reported figures from SEC (XBRL) filings.
What is Veru Inc.'s Net Debt?
Veru Inc.'s Net Debt is -$23.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VERUAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Gain on sale of ENTADFI® assets
Operating loss from continuing operations
Non-operating income (expenses):
Gain on extinguishment of debt
Change in fair value of equity securities
Other income, net
Total non-operating income
Net loss from continuing operations
Net loss
Net loss per basic and diluted common shares and pre-funded warrants outstanding (in dollars per share)